| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Sign In to gain access to subscriptions and/or personal tools.
|
|
|
|||||||
Sign In to gain access to subscriptions and/or personal tools. |
|||||||||
From the UCLA-Orthopaedic Hospital, Los Angeles, California
* Address correspondence to Nick A. Evans, MD, UCLA-Orthopaedic Hospital, 2400 South Flower Street, Los Angeles, CA 90007 (e-mail: drnicke{at}yahoo.com).
Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone. According to surveys and media reports, the legal and illegal use of these drugs is gaining popularity. Testosterone restores sex drive and boosts muscle mass, making it central to 2 of society’s rising preoccupations: perfecting the male body and sustaining the male libido. The anabolic effects of AAS have been questioned for decades, but recent scientific investigation of supraphysiologic doses supports the efficacy of these regimens. Testosterone has potent anabolic effects on the musculoskeletal system, including an increase in lean body mass, a dose-related hypertrophy of muscle fibers, and an increase in muscle strength. For athletes requiring speed and strength and men desiring a cosmetic muscle makeover, illegal steroids are a powerful lure, despite the risk of subjective side effects. Recent clinical studies have discovered novel therapeutic uses for physiologic doses of AAS, without any significant adverse effects in the short term. In the wake of important scientific advances during the past decade, the positive and negative effects of AAS warrant reevaluation. Guidelines for the clinical evaluation of AAS users will be presented for sports medicine practitioners.
Key Words: anabolic steroids • testosterone • androgen • anabolism • athletic performance • doping
This article has been cited by other articles:
|
|
 |
|
  H. Rashid, S. Ormerod, and E. Day Anabolic androgenic steroids: what the psychiatrist needs to know Advan. Psychiatr. Treat., May 1, 2007; 13(3): 203 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Marqueti, N. A. Parizotto, R. S. Chriguer, S. E. A. Perez, and H. S. Selistre-de-Araujo Androgenic-Anabolic Steroids Associated With Mechanical Loading Inhibit Matrix Metallopeptidase Activity and Affect the Remodeling of the Achilles Tendon in Rats Am. J. Sports Med., August 1, 2006; 34(8): 1274 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Saudan, N Baume, N Robinson, L Avois, P Mangin, and M Saugy Testosterone and doping control Br. J. Sports Med., July 1, 2006; 40(suppl_1): i21 - i24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Pereira de Jesus-Tran, P.-L. Cote, L. Cantin, J. Blanchet, F. Labrie, and R. Breton Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci., May 1, 2006; 15(5): 987 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Vicencio, C. Ibarra, M. Estrada, M. Chiong, D. Soto, V. Parra, G. Diaz-Araya, E. Jaimovich, and S. Lavandero Testosterone Induces an Intracellular Calcium Increase by a Nongenomic Mechanism in Cultured Rat Cardiac Myocytes Endocrinology, March 1, 2006; 147(3): 1386 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Vlahopoulos, W. E. Zimmer, G. Jenster, N. S. Belaguli, S. P. Balk, A. O. Brinkmann, R. B. Lanz, V. C. Zoumpourlis, and R. J. Schwartz Recruitment of the Androgen Receptor via Serum Response Factor Facilitates Expression of a Myogenic Gene J. Biol. Chem., March 4, 2005; 280(9): 7786 - 7792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sonneveld, H. J. Jansen, J. A. C. Riteco, A. Brouwer, and B. van der Burg Development of Androgen- and Estrogen-Responsive Bioassays, Members of a Panel of Human Cell Line-Based Highly Selective Steroid-Responsive Bioassays Toxicol. Sci., January 1, 2005; 83(1): 136 - 148. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
